ARDS, Human Clinical Trial
Official title:
Study of the Effects of Bronchoalveolar Lavage Liquid in the ARDS on the Functioning of the Neutrophil Polynuclear System
Firstly, the study assesses the effect of bronchoalveolar lavage fluid (BAL) from patients in
(acute respiratory distress syndrome (ARDS) on the life span of PNNs and on the phagocytosis
of apoptotic cells by macrophages and polynuclear neutrophil (PNN).
Then, the effect of an antibody directed against "high-mobility group box 1" protein (HMGB1)
and the effect of metformin on efferocytosis are studied.
ARDS (acute respiratory distress syndrome) is a syndrome that causes significant mortality
and morbidity. This syndrome is characterized by an alveolitis with polynuclear neutrophil
(PNN). PNNs play an important role in the persistence and in injuries induced by ARDS.
Several animal studies have shown that lesional edema can be increased by two important
mechanisms: the increase in the lifespan of PNNs in the lung and the decrease in the
phagocytosis capacities of apoptotic cells (efferocytosis) by macrophages and PNNs.
However, confirmation of these data in humans does not exist, and knowledge of the mechanisms
that may increase lung damage during ARDS will limit it and thus reduce the mechanical
ventilation time of these patients as well as the mortality associated with ARDS.
" high-mobility group box 1 " (HMGB1) protein may be involved in reducing efferocytosis
capacity. Similarly, activation of AMP-activated protein kinase (AMPk) could restore the
clearance capacity of apoptotic cells in macrophages and PNNs.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06444750 -
Comparison of the Proteome in ICU Patients in Search for TRALI Biomarkers
|
||
| Not yet recruiting |
NCT05306392 -
Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation
|
N/A | |
| Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
| Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
| Completed |
NCT04274296 -
Advisory Lead ARDS Respirator Management
|
||
| Recruiting |
NCT03215316 -
Screening Expiratory Flow Limitation by Flow-time Curve
|
N/A | |
| Recruiting |
NCT04115514 -
Treatment of ARDS With Instilled T3
|
Phase 2 | |
| Not yet recruiting |
NCT05061212 -
The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis
|
||
| Completed |
NCT05693051 -
Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
|
||
| Not yet recruiting |
NCT04556864 -
Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
|
||
| Recruiting |
NCT04174014 -
Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography
|
N/A | |
| Enrolling by invitation |
NCT06164639 -
Potential Biomarkers for Reflux Aspiration-induced Lung Injury.
|
||
| Terminated |
NCT05384379 -
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
|
Early Phase 1 | |
| Completed |
NCT04375735 -
London's Exogenous Surfactant Study for COVID19
|
Phase 1/Phase 2 | |
| Completed |
NCT06224010 -
Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS
|
||
| Not yet recruiting |
NCT04530188 -
Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS
|
Phase 3 | |
| Completed |
NCT03405038 -
Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
|
||
| Recruiting |
NCT05148026 -
Regional Citrate Anticoagulation for RRT During V-V ECMO
|
N/A | |
| Recruiting |
NCT04390360 -
Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction
|
N/A | |
| Completed |
NCT06197256 -
Cardiac Dysfunction in Critically Ill Covid-19 Patients
|